Drug Search Results
More Filters [+]

V-419

Alternative Names: v-419, v 419, v419, Vaxelis
Latest Update: 2024-12-31
Latest Update Note: PubMed Publication

Product Description

V-419 is being developed by Sanofi for the treatment of Neisseria Meningitidis, Bacterial Infections, and Virus Diseases. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01553279?term=V-419&draw=2&rank=1)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MCM Vaccines B.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for V-419

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hepatitis B|Respiratory Syncytial Virus Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CORAL

P3

Recruiting

Respiratory Syncytial Virus Infections

2025-09-30

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination

P3

Completed

Hepatitis B

2021-03-08

Recent News Events